Alexandria Real Estate Equities, Inc. Celebrates 32 Years of Leadership in Life Science Real Estate

On its 32nd anniversary, Alexandria Real Estate Equities, Inc. (NYSE: ARE) commemorates three decades of pioneering advancements in life science real estate. Founded as a garage startup, Alexandria has significantly transformed the commercial landscape by creating life science real estate as a critical asset class. The company's unwavering focus has positioned it as a leader in supporting U.S. health, economic resilience, and national security through innovative real estate solutions.

Transformative Impact on the Life Science Sector

Alexandria has consistently been at the forefront of the life science industry, delivering mission-critical infrastructure and fostering ecosystems that drive innovation. Over 90% of diseases still lack effective treatments, emphasizing the importance of Alexandria's role in enabling advancements within this essential sector.

Industry Challenges and Opportunities

“As the cornerstone of U.S. innovation, the life science industry is navigating a period of change,” stated Joel S. Marcus, executive chairman and founder of Alexandria. “Despite evolving challenges, including shifting research funding priorities and global competition, the need for strong domestic life science investment remains paramount for maintaining U.S. leadership.”

Key Market Performance Metrics

Alexandria's leadership is highlighted by exceptional performance metrics across its Megacampus™ ecosystems:

• In Greater Boston, the San Francisco Bay Area, and San Diego, Alexandria generated 71% of its annual rental revenue as of September 30, 2025, with Megacampus occupancy at 91%.
• From January 1, 2023, to September 30, 2025, Alexandria's leasing volume in these markets exceeded 105% of the total square footage leased by the next five major life science real estate owners combined.
• The firm's tenant retention rate has averaged over 80% over the past five years.

Strategic Importance of Megacampus Ecosystems

These statistics reflect Alexandria's strategic advantage and the growing demand for its Megacampus platform, which is tailored to meet the collaborative needs of the life science industry. Alexandria's commitment to operational excellence fosters strong tenant relationships and enhances its economic sustainability.

Focus on Human Health Initiatives

In 2026, Alexandria prioritizes a groundbreaking public-private partnership with the Foundation for the National Institutes of Health aimed at improving understanding and treatment of depression. The initiative, known as the Multi-Level Assessment & Phenotyping in Depression (MAP-D) program, seeks to modernize clinical trials and enable personalized treatment options for major depressive disorder.

Major depressive disorder affects more than 21 million adults in the U.S. annually, costing over $380 billion per year. The MAP-D program's first clinical study is set to launch in May 2026, coinciding with Mental Health Awareness Month.

About Alexandria Real Estate Equities, Inc.

Founded in 1994, Alexandria Real Estate Equities, Inc. (NYSE: ARE) is an S&P 500® company and a leading life science real estate investment trust (REIT) committed to making a substantial impact in the world. With a current market capitalization of $27.8 billion, Alexandria operates a diverse portfolio across major innovation hubs, including Greater Boston, the San Francisco Bay Area, and San Diego.

The firm’s asset base includes 39.1 million rentable square feet of operational properties and 4.2 million square feet of Class A/A+ properties under construction. Alexandria's strategic approach ensures that it remains a trusted partner to life science companies, providing infrastructure that enhances productivity and attracts world-class talent.

Forward-Looking Statements

This article includes forward-looking statements regarding Alexandria's future initiatives, including research and investment in life sciences. Such statements reflect current intentions and expectations but involve risks and uncertainties that could lead to actual results differing materially from those anticipated.